arrow
O

Ola Blennow

consejo superior de investigaciones cientificas (csic)
H指数:28
被引数:3,551

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hospital at home enables safe and efficient outpatient management of intensively treated acute myeloid leukemia

居家医院使强化治疗的急性髓系白血病患者能够安全高效地进行门诊管理

2026-09-100
OAAI
Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM Candida III Multinational European Observational Cohort Study

非重症监护病房念珠菌血症的临床特征、管理及预后:ECMM念珠菌III多国欧洲观察性队列研究的亚组分析

2026-04-010
OA
Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III Study

持续念珠菌血症的危险因素及预后意义:ECMM Candida III 研究结果

2025-10-150
OAAI
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals

免疫缺陷个体中针对SARS-CoV-2的失调适应性免疫应答

2025-05-060
OA
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
2024-11-010
PRE
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
2023-08-311
OAAI
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG
2023-08-2414
OAAI
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

SARS-CoV-2 mRNA疫苗接种后免疫功能低下个体免疫原性的真实世界评估: 前瞻性临床试验COVAXID的一年随访

2023-08-016
OAAI
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
2023-07-1215
OAAI
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
2023-06-1316
OAAI
Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
2023-06-0156
OAAI
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

新型冠状病毒肺炎血液系统恶性肿瘤患者的尼马曲韦/利托那韦: EPICOVIDEHA登记处的报告

2023-04-0123
OAAI